Premium
Effect of propranolol treatment on bone mass, bone mineral content, bone remodelling, parathyroid function and vitamin D metabolism in hyperthyroidism
Author(s) -
MOSEKILDE L.,
JASTRUP B.,
MELSEN F.,
LUND BI.,
LUND BJ.,
SØRENSEN O. H.,
NIELSEN H. E.,
YDE H.
Publication year - 1984
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1984.tb02095.x
Subject(s) - medicine , endocrinology , bone remodeling , bone mineral , chemistry , iliac crest , parathyroid hormone , bone resorption , cortical bone , calcium , osteoporosis , surgery , anatomy
. The effect of propranolol 160–640 mg/day for 3 months on the accelerated loss of bone matrix and mineral in hyperthyroidism was studied in seventeen patients. A rise in serum thyroxine ( P < 0·01) during the first 3 weeks was followed by a fall ( P < 0·02). Serum triiodothyronine declined during the study ( P < 0·02). The enhanced bone mineral mobilization and collagen turnover continued during treatment and the bone mineral content decreased 3·2% ( P < 0·01). The secondary adaptive changes in serum parathyroid hormone and vitamin‐D metabolites and in renal phosphate handling stayed unchanged. Iliac crest bone biopsies after tetracycline double‐labelling showed initially a high bone turnover ( P < 0·01) with a reduced amount of cortical and trabecular bone ( P < 0·05). Following treatment bone formation rate decreased at both cellular and tissue level ( P < 0·01). No significant changes were observed in the amount of cortical and trabecular bone. The investigation shows that propranolol, in contrast to antithyroid medication, lacks any curative effect on the accelerated bone loss in hyperthyroidism.